Yield10 Bioscience Inc Stock News

Three Yield10 CRISPR Genome-Edited Camelina Lines Were Determined to be Similar to Conventional Camelina Varieties and Not Subject to Regulation Three Yield10 CRISPR Genome-Edited Camelina Lines Were

WOBURN, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced the hiring of Darren Greenfield to serve as the Company�

Yield10 Bioscience Inc (YTEN) shares closed today at 0.8% above its 52 week low of $3.93, giving the company a market cap of $19M. The stock is currently down 19.9% year-to-date, down 43.0% over the past 12 months, and down 97.0% over the past five years. This week, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 1.6%. Trading Activity Trading volume this week was 47.7% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Materials industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -714.2% The company's stock price performance over the past 12 months lags the peer average by 218.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Yield10 Bioscience Inc (YTEN) shares closed 1.0% lower than its previous 52 week low, giving the company a market cap of $20M. The stock is currently down 14.6% year-to-date, down 40.8% over the past 12 months, and down 96.8% over the past five years. This week, the Dow Jones Industrial Average fell 1.3%, and the S&P 500 fell 2.6%. Trading Activity Trading volume this week was 44.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Materials industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -802.0% The company's stock price performance over the past 12 months lags the peer average by 193.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

WOBURN, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, announced today that President and CEO Oliver Peoples, Ph.D. will give a

WOBURN, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, announced today that President and CEO Oliver Peoples, Ph.D. will give a c

WOBURN, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, announced today that management will participate at the Benzinga Global

WOBURN, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, announced today that management will participate at the Benzinga Global Small Cap Conference on December 9, 2021.

WOBURN, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that its Chief Science Officer Dr. Kristi Snell will pres

WOBURN, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that its Chief Science Officer Dr. Kristi Snell will present during the Canola Week 2021 Conference taking place in virtual format November 30 through December 2, 2021.

WOBURN, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that its Chief Science Officer Dr. Kristi Snell will presen

Yield10 Bioscience (NASDAQ:YTEN) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research report issued on Friday, Zacks.com reports. The firm presently has a $6.00 price target on the specialty chemicals companys stock. Zacks Investment Researchs target price would suggest a potential upside of 21.70% from the stocks []

Yield10 Bioscience, Inc. (YTEN) CEO Ollie Peoples on Q3 2021 Results - Earnings Call Transcript

Metabolix, Inc. (YTEN) delivered earnings and revenue surprises of 22.22% and -57.99%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

WOBURN, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that the Company will report its third quarter 2021 financi